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The development of new therapies to induce self-tolerance has been an important medical
health challenge in type 1 diabetes. An ideal immunotherapy should inhibit the autoimmune
attack, avoid systemic side effects and allow β-cell regeneration. Based on the immuno-
modulatory effects of apoptosis, we hypothesized that apoptotic mimicry can help to restore
tolerance lost in autoimmune diabetes.
Objective
To generate a synthetic antigen-specific immunotherapy based on apoptosis features to
specifically reestablish tolerance to β-cells in type 1 diabetes.
Methods
A central event on the surface of apoptotic cells is the exposure of phosphatidylserine,
which provides the main signal for efferocytosis. Therefore, phosphatidylserine-liposomes
loaded with insulin peptides were generated to simulate apoptotic cells recognition by anti-
gen presenting cells. The effect of antigen-specific phosphatidylserine-liposomes in the re-
establishment of peripheral tolerance was assessed in NOD mice, the spontaneous model
of autoimmune diabetes. MHC class II-peptide tetramers were used to analyze the T cell
specific response after treatment with phosphatidylserine-liposomes loaded with peptides.
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Results
We have shown that phosphatidylserine-liposomes loaded with insulin peptides induce tol-
erogenic dendritic cells and impair autoreactive T cell proliferation. When administered to
NODmice, liposome signal was detected in the pancreas and draining lymph nodes. This
immunotherapy arrests the autoimmune aggression, reduces the severity of insulitis and
prevents type 1 diabetes by apoptotic mimicry. MHC class II tetramer analysis showed that
peptide-loaded phosphatidylserine-liposomes expand antigen-specific CD4+ T cells in vivo.
The administration of phosphatidylserine-free liposomes emphasizes the importance of
phosphatidylserine in the modulation of antigen-specific CD4+ T cell expansion.
Conclusions
We conclude that this innovative immunotherapy based on the use of liposomes constitutes
a promising strategy for autoimmune diseases.
Introduction
An important goal in type 1 diabetes (T1D) prevention is the arrest of the autoimmune reaction
to β-cells. The uptake of apoptotic cells by antigen presenting cells, called efferocytosis, is an es-
sential process in immunological tolerance induction [1, 2]. Apoptotic cells exhibit surface
changes, especially exposure of the plasma membrane inner leaflet phospholipid phosphatidyl-
serine (PS) that distinguish them from viable cells and allow recognition by efferocytic receptors
[3]. Many of these receptors of eat-me signals-TIM-4, CD14, BAI1 and αvβ3 integrin, among oth-
ers- may contribute to form the engulfment synapse [4]. Defective efferocytosis is associated to
T1D and other autoimmune diseases [5, 6]. The efficacy of an antigen-specific cell immunothera-
py based on apoptosis in preventing experimental T1D was previously demonstrated [7] and
consists in dendritic cells (DCs) loaded with apoptotic β-cells, which reestablishes immunological
tolerance through suppressive DCs and prostaglandin E2 (PGE2) production [8].
Due to the difficulty in obtaining and standardizing β-cell apoptotic bodies, our interest has
been drawn to whether peripheral tolerance may be restored by liposomal microparticles con-
taining β-cell antigens, as an alternative source of apoptotic β-cells. Liposomes have the advan-
tages of being easy to prepare, customize and administer, and of constituting a low-cost strategy
compared to other current immunotherapies. Moreover, liposomes protect encapsulated anti-
gens from degradation by proteases in the plasma. Lipid-based nanotechnology is an innovative
area of great scientific interest that includes liposomes, which are currently used clinically as vehi-
cles for anticancer drugs, vaccines, and in the treatment of autoimmune diseases [9–11].
Several groups have demonstrated that the use of PS-liposomes may inhibit immune re-
sponses through down modulation of macrophage and DCs [12–16]. Since antigen specific PS-
liposomes resemble apoptotic cells in inhibiting maturation and immunostimulatory function
of DCs, these liposomal microparticles could be optimum vehicles to restore tolerance to auto-
antigens thus preventing the progression of autoimmunity.
Materials and Methods
Ethics Statement
In vivo experiments were performed in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the Generalitat de Catalunya, Catalan
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Government and the Principles of laboratory animal care (NIH pub.85–23 revised 1985; http://
grants1.nih.gov/grants/olaw/references/phspol.htm). The protocol was approved by the Com-
mittee on the Ethics of Animal Experiments of the Germans Trias i Pujol Research Institute.
Mice
Wild-type NODmice were bred in our own facility and kept under specific pathogen-free con-
ditions, in a 12 h dark/12 h light cycles with food and water ad libitum. Only prediabetic 8–12
week old females were included in the study. NOD.Foxp3EGFP mice were generated in-house
using a speed congenic approach by backcrossing B6.Foxp3EGFP animals into the NOD back-
ground while monitoring 15 independent Idd loci as described [17], and used to study the ex-
pansion of Foxp3+ CD4+ T cells. Mice were sacrificed by cervical dislocation.
Peptides and liposomes
Insulin peptides were selected because they are target epitopes in autoimmune diabetes [18]
and β-cell specific. Peptide A, from insulin A chain (21 aa, N-start-GIVDQCCTSICSLYQLEN
YCN-C-end) and peptide B, from insulin B chain (30 aa, N-start-FVKQHLCGSHLVEALYL
VCGERGFFYTPMS-C-end) were chosen (Genosphere Biotechnologies, Paris, France). The
2.5mi peptide (AHHPIWARMDA), a mimotope for the diabetogenic CD4+ T cell clone BDC-
2.5, has been described [19] and was selected for tetramer experiments. The peptide derived
from glucose-6-phosphate isomerase (GPI) 282–292 (GPI282–292, LSIALHVGFDH) (GL Bio-
chem, Shanghai, China) was used as irrelevant control for tetramer staining [19]. Peptides were
>95% pure and Trifluoroacetic acid was removed. Liposomes were composed of 1,2-dioleoyl-
sn-glycero-3-phospho-L-serine (sodium salt) (DOPS) and 1,2-didodecanoyl-sn-glycero-
3-phosphocholine (DLPC, Lipoid, Steinhausen, Switzerland), and cholesterol (CH, Sigma Al-
drich, Saint Louis, MO). Lipid-conjugated fluorescent dye Oregon Green 488 1,2-dihexadeca-
noyl-sn-glycero-3-phosphoethanolamine (DHPE) was purchased from Invitrogen (Carlsbad,
CA). Alexa Fluor 750 was obtained from Invitrogen and was conjugated with the lipid 1,2-Dio-
leoyl-sn-glycero-3-phosphoethanolamine (Avanti Polar Lipids, Alabaster, AL). The liposomes
were prepared using the thin film hydration method from a lipid mixture of PS, PC and CH at
1:1:1.33 molar ratio, respectively [15], under sterile conditions. The final concentration of lipid
was 30 mM. Lipids and lipid-conjugated fluorescent dyes were dissolved in chloroform and the
solvent was removed by evaporation under vacuum and nitrogen. The lipids were hydrated
with the appropriate buffer (PBS, 0.5mg/mL solution of insulin peptide A, insulin peptide B or
2.5mi peptide) and the liposomes obtained were homogenized to 1 μm by means of an extruder
(Lipex Biomembranes, Vancouver, Canada). Encapsulation efficiencies (EE) were calculated
according to the equation EE(%) = [(Cpeptide,total-Cpeptide,out)/Cpeptide,total] x100, where Cpeptide,
total is the initial peptide A or B concentration and Cpeptide,out is the concentration of non-en-
capsulated peptide. To measure the Cpeptide,out, all liposome suspensions were centrifuged at
110000g for 30 min at 10°C. The concentration of non-encapsulated peptide was assessed in
supernatants by PIERCE BCA protein assay kit (Thermo Fisher Scientific Inc., Rockford, IL).
In addition to PS-liposomes loaded with insulin peptides (PSAB-lipo) or 2.5mi peptide
(PS2.5mi-lipo), empty liposomes were generated as controls (PS-lipo). Moreover, liposomes
with PC and CH but without PS were generated as controls, empty (PC-lipo) or loaded with
2.5mi peptide (PC2.5mi-lipo), following the same methodology used in PS-liposomes. Particle
size distributions and stability of liposomes-expressed as zeta potential (z)- were measured by
dynamic light scattering (DLS) using Malvern Zetasizer (Malvern Instruments, UK) in undilut-
ed samples. The morphology and lamellarity of liposomes were examined using cryogenic
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transmission electron microscopy (cryo-TEM) in a JEOL-JEM 1400 microscope (Jeol Ltd.,
Tokyo, Japan).
Dendritic cells and uptake of liposomes
DCs were generated from bone marrow progenitor cells in culture medium with GM-CSF
(1000 U/ml; Prospec, Rehovot, Israel) [7]. Control DCs were either cultured in basal conditions
to obtain immature DCs (iDCs) or with lipopolysaccharide (LPS, 100ng/ml; Sigma) for 24
hours to obtain mature DCs (mDCs). DCs purity was assessed by CD11c-PECy7 staining (BD
Biosciences, San Jose, CA). Cell viability was determined by annexin V-phycoerythrin (PE)
and 7aad staining (BD Biosciences) and cells were counted by flow cytometry (Perfect Count
Microspheres, Cytognos, Salamanca, Spain). Preliminary experiments were performed to de-
fine optimal conditions. To determine whether liposome uptake by DCs occurs through phago-
cytosis, in vitro assays were performed by coculturing DCs with 100 μM fluorescence labeled
liposomes (Oregon green 488 DHPE, Invitrogen) during 5 min to 4 hours at 37°C and at 4°C.
After extensively washing in PBS to remove the liposomes attached to the cell membrane, lipo-
some capture was determined by flow cytometry (FACSCanto II, BD Biosciences).
Flow cytometry
The expression of costimulatory molecules CD40 and CD86 was assessed in the membrane of
DCs by flow cytometry (FACSCanto II). DCs were cocultured with 1mM liposomes during 2
hours and maintained in basal conditions or matured with 100 ng/ml LPS (Sigma) for addi-
tional 24 hours. DCs were then stained with monoclonal antibodies to mouse CD11c-PECy7,
CD40-allophycocyanin (APC), CD86-PE (BD Biosciences), class I MHC H-2Kd-eFluor450
and class II MHC I-Ad-APC (eBioscience, San Diego, CA). Corresponding fluorescence minus
one (FMO) staining was used as control. Data were analyzed using FlowJo software (Tree Star,
Ashland, OR).
ELISA
The production of PGE2 was assessed by ELISA (PGE2 EIA Kit-Monoclonal; Cayman Chemi-
cals, Ann Arbor, MI), in supernatants obtained from cell cultures, 24 hours after liposome cap-
ture by DCs. Limit of detection: 80% B/B0: 15 pg/ml. Sensitivity: 50% B/B0: 50 pg/ml. Results
were expressed as pg of PGE2/10
6 cells.
T cell proliferation assays and cytokine production
DCs were loaded with 1 mM liposomes (empty or loaded with insulin peptides) during 2 hours
in the presence of insulin (20μg/ml, Sigma). DCs were cultured in basal conditions or matured
with LPS (100 ng/ml, Sigma) for additional 24 hours to determine tolerogenic function stabili-
ty. T cells were obtained after mechanical disruption of spleen and purified by negative selec-
tion using antibodies to CD19-PE, CD16/32-PE, CD11c-PECy7 (BD Biosciences), CD11b-PE
(ImmunoTools GmbH, Friesoythe, Germany), and sorted (FACSAria II, BD Biosciences) as
previously described [8]. 104 DCs were then cocultured with 105 T lymphocytes (1:10 ratio). As
a control, T lymphocytes (105) were cultured in basal conditions. After 5 days, cells were pulsed
with 1 μCi of (3H)-thymidine (Perkin Elmer, Waltham, MA) for an additional 16 hours. Cells
were harvested (Harvester 96, Tomtec Inc., Hamden, CT) and analyzed using a scintillation
counter (1450 Microbeta, TriluxWallac, Turku, Finland). T cell proliferation was expressed as
counts per minute (c.p.m). Cytokine production was assessed using The Mouse Th1/Th2/Th17
kit (CBA system; BD Biosciences) in supernatants from proliferation assays. Data were
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analyzed using CBA software. The production of TGF-β was determined using Human/Mouse
TGF-β1 Ready-SET-Go! (eBioscience).
In vivo tracking of liposomes by bioimaging
In vivo and ex vivo near-infrared fluorescence imaging was performed using the Pearl Impulse
imaging system (LI-COR, Lincoln, NE). NOD mice were anesthetized with ketamine/xylazine
at 50 and 5 mg/kg body weight, respectively. In vivo imaging was performed at 6, 24, and 48
hours after intraperitoneal (i.p.) administration of 3.5 mg of fluorescence labeled PS-liposomes
(Alexa Fluor 750, Invitrogen) in 200 μl of saline solution. At the end of every checkpoint, peri-
gonadal adipose tissue, kidney, spleen, pancreas, pancreatic lymph nodes, mesenteric lymph
nodes, liver, mediastinal lymph nodes and thymus were harvested, washed in PBS, and imaged
ex vivo using the Pearl Impulse system (LI-COR). Fluorescent signal intensity was semi-quanti-
tatively assessed: Fluorescence level was normalized by subtracting the background and repre-
sented as a relative index of fluorescence in each organ (RFU) / grams of tissue.
Type 1 diabetes prevention and insulitis score
NODmice at 8 weeks of age-normoglycemic and without clinical symptoms of the disease-
were treated with a single i.p. dose of 3.5 mg of PS-liposomes (empty or peptide-filled) in
200 μl saline solution. A sham-control group, which only received saline solution, was also in-
cluded. A minimum of 12 animals per group was analyzed. Mice were monitored daily for
urine glucose using Glucocard strips (Menarini, Barcelona, Spain), and weekly for body weight
until 30 weeks of age. Mice with glycosuria were confirmed diabetic when the blood glucose
level was>300 mg/dl. Insulitis score was determined at the end of the study in all non-diabetic
mice. Briefly, pancreata were snap frozen in an isopentane/cold acetone bath. Cryosections of
5 μm were obtained at non-overlapping levels, stained with hematoxylin and eosin, and ana-
lyzed by two independent observers. A minimum of 40 islets per animal was analyzed. Insulitis
was scored as described elsewhere [20]: 0, no insulitis; 1, peri-insular; 2, mild insulitis (<25%
of the infiltrated islet); 3, 25–75% of the islet infiltrated; 4,>75% islet infiltration.
In vivo antigen specific assay and MHC class II tetramer analysis
Prediabetic NOD and NOD.Foxp3EGFP mice were treated with a single 3.5 mg i.p. dose of
2.5mi peptide-loaded PS-liposomes (PS2.5mi-lipo) in 200 μl saline solution. Control groups
were treated with empty PS-liposomes, 2.5mi peptide-amount calculated based on encapsula-
tion efficiency- or saline solution (sham). Moreover, PS-free liposomes, empty (PC-lipo) and
loaded with 2.5mi peptide (PC2.5mi-lipo), were also administered as controls. At day 4 after
the treatment, spleen, pancreatic lymph nodes and mediastinal lymph nodes were harvested
and cell suspension was obtained through mechanical disruption. Soluble Ag7 MHC molecules
complexed to the 2.5mi or the GPI control peptide were expressed in Drosophila melanogaster
derived SC2 cells, transfected with DNA plasmids coding for the Ad α-chain containing a bioti-
nylation sequence and the Ag7 β-chain connected N-terminally to 2.5mi or GPI282–292. Mole-
cules were purified and biotinylated using the BirA enzyme (Avidity, CO). Tetramers were
generated by incubation of Ag7 monomers with PE-labeled streptavidin (Columbia Bioscience,
Columbia, MD) in a 5:1 ratio [19, 21, 22]. Antigen-specific T cell analysis was performed as
previously described [19]. Briefly, single-cell suspension was blocked with avidin (Sigma) in
PBS containing 2% FBS and 0.04% NaN3, and stained with PE-labeled MHC-peptide tetra-
mers. Antibodies to CD4-pacific blue (PB), CD8-PECy5, CD19-PECy5, F4/80-PECy5 and
CD11c-PECy5 were used (BioLegend, CA). Dead cells were excluded with addition of
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propidium iodide (PI). Flow cytometry was carried out using a FACSCanto II (BD Biosciences)
and data were analyzed using FlowJo software (Tree Star).
Statistical analysis
Statistical analysis was performed using the Prism 5.0 software (GraphPad software Inc., San
Diego, CA), SPSS Statistics 17.0 software (SPSS Inc. Chicago, IL) and “R” software (www.r-
project.org). The analysis of variance (ANOVA) was used for comparisons with several factors.
For paired comparisons, a non-parametric Wilcoxon test was used. Otherwise, MannWhitney
test was applied. For single comparisons, a p-value 0.05 was considered significant. When
several related comparisons were done, a Bonferroni adjustment was performed. Kaplan-Meier
log-rank analysis was used for comparisons between survival curves.
Results
Phosphatidylserine (PS)-presenting liposomes filled with insulin
peptides are captured by DCs
PS-liposomes were prepared with DOPS/DLPC/CH at 1:1:1.33 molar ratio to present PS on
their surface. Empty liposomes presented a mean diameter of 996.71±89.42 nm (mean±SD)
with a polydispersity index (PdI) of 0.31±0.05. Zeta potential measurements revealed a net sur-
face charge of -29.26±2.82 mV on PS-liposomes. When PS-liposomes were loaded with peptide
A or B from mouse Insulin2, the mean diameter was 1051.43±45.15 nm (PdI = 0.31±0.06) and
968.57±86.32 nm (PdI = 0.27±0.08), respectively. Encapsulated liposomes had a negative sur-
face charge of -30.79±2.35 mV for peptide A and -29.44±1.48 mV for peptide B. The mean of
percentage of encapsulation was 41.07±23.58% for peptide A and 87.44±4.54% for peptide B
(Table 1). Cryo-TEM analysis revealed a multivesicular vesicle morphology (Fig 1A).
Time course analysis (Fig 1B) confirmed that 75.20±6.38% of phagocytosis was achieved
after 5 min of coculture at 37°C. As expected, OG488 signal was significantly higher (p<0.001,
and p<0.01) in each checkpoint when compared to the same experiment performed at 4°C. Fig
1C shows liposome capture by DCs after 30 min of coculture at 37°C. We observed greatly de-
creased signal in experiments performed at 4°C, confirming the capture of liposomes
by phagocytosis.
The capture of PS-liposomes by iDCs induces a semimature phenotype
Viability of DCs after coculture with liposomes was always similar to control DCs even after a
proinflammatory stimulus (Fig 2A), regardless of the dose (range 100–1000 μM, data not
shown). We next examined whether liposome capture affected the expression of membrane
MHC and costimulatory molecules (Fig 2B). The expression of CD86 and CD40 in iDCs mem-
brane slightly increased after PS- or PSAB-liposome capture (p<0.05), suggesting that iDCs
had acquired a semimature phenotype, a feature of tolerogenic DCs. After LPS exposure,
Table 1. Insulin-loaded liposome characteristics.
Liposome type Diameter (nm) Polydispersity index (PdI) Zeta potential (mV) Encapsulation efﬁciency (%)
PS-liposomes 996.71 ± 89.42 0.31 ± 0.05 -29.26 ± 2.82 -
PSA-liposomes 1051.43 ± 45.15 0.31 ± 0.06 -30.79 ± 2.35 41.07 ± 23.58
PSB-liposomes 968.57 ± 86.32 0.27 ± 0.08 -29.44 ± 1.48 87.44 ± 4.54
Data are expressed as mean±SD.
doi:10.1371/journal.pone.0127057.t001
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control DCs significantly increased the membrane expression levels of costimulatory molecules
and activation markers CD40 and CD86 (p<0.05). Also, after the addition of LPS, DCs loaded
with PS- or PSAB-liposomes significantly increased CD86 and CD40 when compared to their im-
mature counterparts (p<0.05) (Fig 2B). Comparisons within mDCs group showed that CD86
expression was lower in mDCs loaded with PSAB-liposomes than PS-liposomes pulsed mDCs
(p<0.05). Also, CD40 expression was lower in mDCs loaded with PS-liposomes when compared
to unloaded mDCs (p<0.05). PS- or PSAB-liposome capture did not significantly increase the ex-
pression of MHC in iDCs. However, a tendency to increase MHC class I and class II expression
was observed after the capture of PS- or PSAB-liposomes by iDCs, and after LPS exposure (Fig 2B).
Based on our previous results [8], PGE2 production by DCs after PS-liposome uptake was
measured. The concentration of PGE2 was significantly increased in the supernatant of iDCs
cocultured with PS-liposomes (p<0.01) or PSAB-liposomes (p<0.05) when compared to iDCs
(Fig 2C).
Impairment of DCs to stimulate autologous T cell proliferation after PS-
liposome uptake
DCs derived from bone marrow progenitor cells were>80% pure (CD11c+). Viability was al-
ways>90%. T cell purity and viability were always over 85% and 90% respectively (S1 Fig).
Fig 1. Liposome features. A) Cryogenic transmission electron microscopy images of PSAB-liposomes. Bar = 0.2 μm. B) Time course analysis of the
capture of 100 μMOG488 labeled PS-liposomes (OG488 PS-liposome) by DCs at 37°C (white squares) and at 4°C (black squares). Results are expressed
as mean±SD of three independent experiments (***p<0.001, **p<0.01, Two-way ANOVA). C) Flow cytometry contour plots of the uptake of PS-liposomes
(OG488+) by DCs (CD11c+). From left to right, control DCs, DCs cocultured with OG488 PS-liposome at 4°C and at 37°C. One representative experiment of
three is shown. Percentage of liposome capture (thick line) is referred to CD11c+ cell subset (thin line).
doi:10.1371/journal.pone.0127057.g001
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The capture of PSAB-liposomes by iDCs did not increase autologous T cell proliferation when
compared to iDCs (Fig 3A). A slight increase in T cell proliferation was observed after the cap-
ture of empty PS-liposomes (p<0.05). As expected, T cell proliferation induced by mDCs was
higher than proliferation induced by iDCs (p<0.05). Interestingly, T cell proliferation induced
by mDCs loaded with PS- or PSAB-liposomes was significantly lower than proliferation
Fig 2. Effects of the capture of PS-liposomes in DCs phenotype. A) DCs viability assessed by annexin V and 7aad staining. White symbols represent
iDCs, before (triangles) and after the capture of PS-liposomes (squares) or PSAB-liposomes (circles), 24 hours after culture. Black symbols represent
viability of mature DCs (mDCs) before (triangles) and after the capture of PS-liposomes (squares) or PSAB-liposomes (circles) after proinflammatory
stimulus (LPS). Lines show the mean of at least eight independent experiments. B) Median of fluorescence intensity (MFI) for CD86, CD40, MHC Class I and
MHC Class II membrane expression on DCs before and after liposome capture (white symbols) and after exposure to LPS (black symbols). Lines show the
mean of at least four independent experiments. Comparisons within each group and between paired maturation conditions showed significant differences
(*p<0.05, Wilcoxon test). C) Quantification of the PGE2 production by immature DCs (iDCs) in culture medium (med, white triangles), loaded with PS-
liposomes (PS-lipo, white squares) or PSAB-liposomes (PSAB-lipo, white circles), after 24 hours of culture. Data are represented as pg/106 cells. Lines show
the mean of a minimum of seven independent experiments. Comparisons between groups showed significant differences (**p<0.01 and *p<0.05, Wilcoxon
test).
doi:10.1371/journal.pone.0127057.g002
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induced by unloaded mDCs (p<0.05), even after LPS stimulus, showing the functional effect of
liposomes on mDCs. Predictably, purified T cells cultured without DCs did not show prolifera-
tion (0.07±0.03 c.p.m. x 103, mean±SD).
The uptake of autoantigen-loaded liposomes by iDCs does not alter
cytokine profile
T cells cocultured with iDCs loaded with PS- or PSAB-liposomes displayed a cytokine profile
(IFN-γ, IL-17A) similar to unloaded iDCs (Fig 3B). After LPS stimulus, T cells cocultured with
mDCs or mDCs loaded with PS- or PSAB-liposomes display a tendency to increase the secre-
tion of IFN-γ and IL-17A when compared to their iDCs counterparts. However, a trend toward
lower IFN-γ and IL-17A secretion was observed in PSAB-loaded mDCs condition compared
Fig 3. Impaired DCs’ ability to induce autologous T cell proliferation after PS-liposomes capture, and cytokine secretion. A) Autologous proliferation
of T cells (c.p.m. for 3H thymidine assay) after stimulation induced by iDCs, before (white triangles) and after the capture of PS-liposomes (white squares) or
PSAB-liposomes (white circles), with insulin (20 μg/ml) at a ratio of 1:10 for 6 days. Black symbols represent proliferation induced by mature DCs (mDCs)
before (triangles) and after the capture of PS-liposomes (squares) or PSAB-liposomes (circles), previously activated with proinflammatory stimuli LPS
(100 ng/ml). Lines show the mean of seven independent experiments. Comparisons within each group and between paired maturation conditions showed
significant differences (*p<0.05, Wilcoxon test). B) Cytokine production in T cell proliferation experiments. Levels of IFN-γ and IL-17A were measured in
supernatants from T cell proliferation experiments induced by iDCs, DCs loaded with empty liposomes (PS-lipo) and DCs loaded with liposomes with insulin
peptides (PSAB-lipo) in basal conditions (white bars) or after 24 hours with LPS (black bars). Results are expressed as mean±SEM from four independent
experiments. Comparisons within each group and between paired maturation conditions were not able to detect significant differences (p<0.05, Wilcoxon
test). “<d”means values below the standard.
doi:10.1371/journal.pone.0127057.g003
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with unloaded mDCs. No differences were observed in IL-6, TNF and TGF-β secretion by
iDCs and mDCs due to the uptake of PS- or PSAB-liposomes. IL-2, IL-10 and IL-4 were not de-
tected in any condition of the assay (data below the detection limit) (S2 Fig).
In vivo tracking of liposomes
To determine liposomes biodistribution, fluorescence labeled PS-liposomes were i.p. adminis-
tered to NODmice. The ex vivo analysis of the organs showed that, 24 hours post administra-
tion, fluorescent signal took place primarily in perigonadal adipose tissue, mediastinal lymph
nodes, pancreatic lymph nodes, pancreas, spleen, mesenteric lymph nodes and liver, whereas
the minimum signal was detected in kidney and thymus (Fig 4). Only traces of fluorescent sig-
nal were detected in lungs.
Insulin peptide-filled PSAB-liposomes decrease T1D incidence and
reduce insulitis in NODmice
NODmice were treated with a single dose of immunotherapy during the prediabetic period (8
weeks old). No significant differences were found in body weight in mice treated with PSAB-li-
posomes, PS-liposomes, or saline solution (data not shown). As expected, animals from the
sham-control group developed diabetes from the age of 11 weeks and with a final incidence of
84.62% (Fig 5). The treatment with empty PS-liposomes resulted in a disease incidence of 83.33%
starting the disease at 15 weeks of age. No significant differences were found between both groups.
Mice treated with PSAB-liposomes containing β-cell autoantigens showed a T1D incidence of
50%, significantly lower than sham group (p0.05) and slightly delayed, starting at 16 weeks of
age. Insulitis score was determined at the end of the follow-up period rid="_Ref959725601"
(Fig 6A) As expected, mice in the sham group showed a high degree of insulitis score (2.22±
0.29, mean±SD). Mice treated with PS-liposomes showed a similar insulitis degree (2.12±0.46)
than sham group. Mice treated with PSAB-liposomes displayed a significant reduction in insu-
litis (1.61±0.47) when compared to the sham group (p<0.05) and, a biological reduction, al-
though non-significant, when compared to mice treated with PS-liposomes. In mice treated
Fig 4. Tracking of PS-liposomes. Histogram of ex vivo relative fluorescent signal (RFU, Relative
Fluorescence Units/g tissue) in organs from NODmice 24 hours after the administration of labeled PS-
liposomes (Alexa Fluor 750). PAT, perigonadal adipose tissue; K, kidney; S, spleen; P, pancreas; PLN,
pancreatic lymph nodes; MLN, mesenteric lymph nodes; L, liver; MDLN, mediastinal lymph nodes; T, thymus.
Results are mean±SEM of three independent experiments.
doi:10.1371/journal.pone.0127057.g004
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with PSAB-liposomes, 52.31% of the islets remained non-destructed-insulitis free or with peri-
insulitis-, whereas 35.39% and 31.69% of the islets were non-destructed in the sham and the
PS-liposomes groups, respectively (Fig 6B)
Autoantigen-loaded liposomes induce an antigen-specific T cell
response
To test how peptide-loaded PS-liposomes affected antigen-specific CD4+ T cells in vivo, we car-
ried out tetramer staining experiments. As functional Ag7/insulin peptide tetramers were not
available, we used the 2.5mi peptide instead. 2.5mi is a strong mimotope agonist peptide for
the diabetogenic CD4+ T cell clone BDC-2.5 [23, 24], and Ag7/2.5mi tetramers enable the
detection of a natural CD4+ T cell population, termed 2.5mi+ T cells, that share antigen
Fig 6. Reduction in insulitis following administration of PSAB-liposomes. A) Insulitis score from non-
diabetic mice at the end of the follow-up (30 weeks), sham (n = 4), PS-liposomes (PS-lipo, n = 3) and PSAB-
liposomes containing autoantigens (PSAB-lipo, n = 6). Results are mean±SD (*p0.05, MannWhitney test).
B) Percentage of islets in each of the infiltration categories: White = 0, no insulitis; Dotted = 1, peri-insular;
Striped = 2, mild insulitis (<25% of the infiltrated islet); Squared = 3, 25–75% of the islet infiltrated; Black = 4,
>75% islet infiltration.
doi:10.1371/journal.pone.0127057.g006
Fig 5. Immunotherapy using PS-liposomes filled with insulin peptides decreases T1D incidence.
Cumulative incidence (percentage) of T1D in NODmice treated with PSAB-liposomes (PSAB-lipo, circles,
n = 12), PS-liposomes (PS-lipo, squares, n = 18), and sham group (triangles, n = 26). Significant differences
were found when compared group treated with PSAB-liposomes versus sham group (*p0.05, Kaplan-Meier
log-rank analysis).
doi:10.1371/journal.pone.0127057.g005
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recognition with this T cell clone in NODmice [19]. PS2.5mi-liposomes presented a mean di-
ameter of 875.37±63.27 nm (mean±SD) with a PdI of 0.35±0.13. Zeta potential measurement
revealed a net surface charge of -32.60±2.18 mV. The mean of percentage of encapsulation
was 22.94±12.72%. Empty PS-liposomes were used as controls as described above. Additional
controls were empty PC-liposomes and PC2.5mi-liposomes. Empty PC-liposomes showed a
mean particle size of 1971.50±895.90 nm with a PdI of 0.69±0.44 and a net surface charge of
-4.34±0.07mV. PC2.5mi-liposomes presented a mean particle size of 2055.33±353.23 nm with
a PdI of 0.35±0.17, a net surface charge of -4.52±0.34mV and a percentage of encapsulation
of 16.68±2.90. This low encapsulation efficiency was due to the low affinity of the positively
charged peptide to a much less negatively charged PS-free liposome, in comparison to PS-lipo-
somes, as described [25].
The treatment with one dose of PS2.5mi-liposomes significantly expanded antigen-specific
CD4+ T cells (p<0.001)-at day 4 after the i.p. injection- when compared to treatment with sa-
line solution, 2.5mi peptide or PS-liposomes (Fig 7). This effect was detected in the spleen, pan-
creatic lymph nodes and mediastinal lymph nodes. PC2.5mi-liposomes induced a lower
response of antigen-specific CD4+ T cells than PS2.5mi-liposomes in PLN and MDLN (Fig 7).
We next examined the generation of antigen-specific Foxp3+ CD4+ T after PS2.5mi-lipo-
some administration using NOD.Foxp3EGFP reporter mice. It has been shown that these mice
generate 2.5mi+ T cells as well as Foxp3+ Treg with the same specificity [17]. Antigen-specific
CD4+ T cells, both Foxp3- T cells and Foxp3+ T cells, were expanded in the spleen, PLN and
MDLN frommice treated with PS2.5mi-liposomes (S3 Fig). A 29–36 fold stronger antigen-spe-
cific CD4+ Foxp3- T cell proliferation, and a 4–17 fold stronger antigen-specific CD4+ Foxp3+
T cell proliferation were detected after PS2.5mi-liposomes treatment, when compared to sham
group (S3B Fig). Taken together, our results show that PS2.5mi-liposome administration favors
antigen-specific CD4+ T cell expansion, observed in the Foxp3+ as well as in the Foxp3- T
cell compartments.
Discussion
Apoptotic cells, when engulfed by antigen presenting cells, contribute to the maintenance of
self-tolerance [26]. Based on this feature, we have designed a synthetic strategy to arrest auto-
immunity against β-cells, consisting in liposomal microparticles designed to mimic apoptotic
cells in terms of PS recognition and filled with insulin peptides. These liposomes prevent T1D
through specific reestablishment of tolerance.
Indeed, we have previously demonstrated that the tolerance to β-cells is restored by the ad-
ministration of tolerogenic DCs loaded with apoptotic β-cells [7], through tolerogenic features
and suppressive effects acquired by DCs after efferocytosis [8]. Due to the difficulty in obtain-
ing, preserving and standardizing apoptotic cells, an important issue was: how could apoptotic
β-cells be mimicked for therapeutic purposes? A central event of apoptotic cells is the loss of
phospholipid arrangement and the exposure of phosphatidylserine component, which is pres-
ent in the inner layer of the cell membrane and will provide the main signal for efferocytosis.
Therefore, PS-liposomes filled with insulin peptides were prepared, in the size range for an effi-
cient phagocytosis [27, 28] and with multivesicular vesicles morphology, with advantages in
terms of encapsulation [29] and immunological activity [30]. Several groups have demonstrat-
ed the anti-inflammatory effects of PS-liposomes [12–15]. This feature is dependent on the ex-
posure of phosphatidylserine [16, 31] and mimics apoptotic cell clearance, an immunologically
silent event [32]. Anionic liposomes, composed of phosphatidylserine, phosphatidylcholine,
and cholesterol, interact with DCs promoting phagocytosis [33]. Therefore, PS-liposomes
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could be optimum vehicles of β-cell autoantigens, by simulating apoptotic cell recognition and
inhibiting maturation and immunostimulatory function of DCs [34].
Insulin is an obvious target for antigen specific interventions in humans and NODmice.
Oral administration of insulin resulted in disease prevention in animal models [35, 36], but in
Fig 7. Antigen-specific CD4+ T cell expansion 4 days after i.p. administration of PS2.5mi-liposomes to NODmice. A) Representative flow cytometry
contour plots of the percentage of 2.5mi+ CD4+ T cells in the spleen, pancreatic lymph nodes (PLN) and mediastinal lymph nodes (MDLN) (gated on CD19-,
CD8-, F4/80-, CD11c-, PI- and CD4+ cells) in the sham group and after the administration of PS2.5mi-liposomes or PC2.5mi-liposomes. Left panel: Ag7/2.5mi
tetramer staining. Right panel: control staining with Ag7/GPI282–292 tetramer. B) Detection of 2.5mi
+ CD4+ T cells in the spleen, PLN and MDLN from 4–8 mice
pooled from 4 independent experiments after the administration of saline solution (white triangles, n = 6), 2.5mi peptide (white rhombus, n = 5), PS-liposomes
(white squares, n = 4), PS2.5mi-liposomes (white circles, n = 8), PC-liposomes (black squares, n = 5) or PC2.5mi-liposomes (black circles, n = 4).
Comparisons between groups showed significant differences (***p<0.001, One-way ANOVA and Bonferroni multiple comparison test).
doi:10.1371/journal.pone.0127057.g007
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humans, the results have not been very encouraging. An added benefit of liposome approach is
the delivery of insulin peptides along with PS, a combination that can contribute to a stable
and long-term specific tolerance reestablishment. To avoid possible biological effects of insulin,
we decided to encapsulate the peptides corresponding to the whole A and B chain of insulin.
These two peptides contain well-known β-cell specific target epitopes in T1D [18, 35, 37]. Pep-
tide A showed a reduction in the encapsulation when compared to peptide B, a difference at-
tributed to aminoacid composition and peptide solubility. To improve this immunotherapy,
additional T1D autoantigens should be evaluated for encapsulation in terms of solubility, size
and antigenicity [38]. After liposome engulfment by DCs, autoantigens would be presented to
CD4+ T lymphocytes through MHC class II molecules and to CD8+ T lymphocytes by cross
presentation [39] in tolerogenic forms [40, 41].
In vitro experiments revealed important immunological features. First, PS- and PSAB-lipo-
somes were safely phagocytosed by DCs because liposomes do not degenerate into toxic side
products, such as necrotic bodies. Second, after liposome uptake, iDCs slightly increased
CD86, CD40 membrane expression and showed a biological, although non significant, increase
of MHC class II expression. This phenotype suggests that DCs acquired a semimature pheno-
type after liposome capture, a feature of tolerogenic DCs [42]. Moreover, after the uptake of
PS- or PSAB-liposomes, DCs were poor stimulators of autologous T cell proliferation, even
after proinflammatory stimulus. Third, the liposome uptake induced PGE2 secretion by DCs, a
tolerogenic mediator of antigen presenting cells [8, 43, 44]. It is well known that the production
of PGE2 by PS-liposomes depends on the exposure of PS and ligation of its receptor; in fact,
PGE2 secretion by DCs is not induced by phosphatidylcholine liposomes [14, 45]. And finally,
given the role of IL-17 and IFN-γ in β-cell apoptosis and T1D [46], we showed that IL-17A and
IFN-γ production was not increased in T cell proliferation assays induced by DCs after autoan-
tigen-loaded liposome uptake. Also, a trend toward lower cytokine secretion was observed
even after a proinflammatory stimulus, suggesting that PSAB-liposomes contribute to toler-
ance reestablishment, by antigen specific memory cells. Taken together, these results suggest
that PSAB-liposomes may inhibit the DCs’ ability to stimulate T cell response and may pro-
mote tolerance, similar to that induced by apoptotic cells in an antigen-specific manner [8].
We are well aware that liposome design and administration pattern should be improved to bet-
ter simulate apoptotic β-cells. In this sense, liposomes could be customized, encapsulating pep-
tides from other T1D autoantigens, thus inactivating the autoreactive T cell repertoire. Also,
the administration pattern must be optimized to improve the effect of the immunotherapy.
Another important issue for this immunotherapy is biodistribution. Fluorescent signal was
detected in the pancreatic lymph nodes, spleen and pancreas, supporting a contribution to an
effective local and systemic effect after tolerogenic antigen presentation. The signal was also de-
tected in the mediastinal lymph nodes, suggesting that liposomes may translocate to the thy-
mus, thus contributing to central tolerance as described after i.p. administration of
nanoparticles [47]. The high amount of signal in the perigonadal adipose tissue can be due to
liposome affinity for this tissue. No signal was observed in lungs and heart. These results, ob-
tained 24 h after i.p. administration, suggest that signal can be predominantly from phagocytes
that have captured PS-liposomes because liposome size and PS promote efferocytosis. In fact,
in vivo experiments demonstrated that PS-liposomes are captured by phagocytes in 3 hours
[15], and the uptake is PS-dependent. Bioimaging results were as expected after i.p. administra-
tion of large PS-liposomes [48, 49] and agree with previously reported data in the biodistribu-
tion of intraperitoneally injected DCs from NODmice that migrate to pancreatic lymph nodes,
remaining for up to one week [50]. However, additional experiments should be performed to
go in depth in this matter.
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In vivo experiments demonstrated that PSAB-liposomes decrease T1D incidence and slight-
ly delay the onset of the disease. However, no effect was observed when NODmice received
empty PS-liposomes. Empty liposomes display anti-inflammatory effects [15] that fit well with
our results in terms of costimulatory molecules expression, anti-inflammatory mediators and
T cell proliferation. However, they had no effect in T1D incidence, because the arrest of the au-
toimmune attack is an adaptive immunity mechanism induced through tolerogenic antigen
presentation. This antigen specificity is well supported by our previous study using apoptotic
cells with irrelevant antigenic content for T1D [7]. As expected, the prevention of T1D by
PSAB-liposomes correlates with the reduction of insulitis, keeping more than 50% of the islets
with β-cell mass preservation. In this sense, the here reported results are similar to those ob-
tained with apoptotic β-cells [7] engulfed by DCs. We are conscious of the relevance of the dis-
ease stage for a successful immunointervention. In this sense, liposome-based therapy could be
optimized by treating NODmice at earliest stages of the autoimmune attack, during the re-
cruitment of innate cells to the islets and the initiation of diabetogenic T cell response [51].
This stage-from 4 weeks of age- is characterized by a type 1 interferon signature, and can be the
best time to start immunotherapy [52].
The MHC class II tetramer analysis was performed as a tool for direct identification of anti-
gen-specific CD4+ T cells expanded by tolerogenic DCs. The results confirm that the adminis-
tration of PS-liposomes loaded with 2.5mi peptide resulted in a fast expansion of antigen-
specific CD4+ T cells, which is typical for a memory response [53]. No effect was observed
when mice were treated with empty PS-liposomes or with 2.5mi peptide. As expected, PS-free
liposomes loaded with peptide induced a lower response of antigen-specific CD4+ T cells than
PS-liposomes in PLN and MDLN, emphasizing the importance of PS as an active component
of the liposome in the modulation of antigen-specific CD4+ T cell expansion. It is well known
that PS is the main ‘eat me’ signal in the engulfment process, but also acts as a ‘tolerate me’ sig-
nal in phagocytes [54]. Because PS-liposomes with autoantigens prevent T1D, it is reasonable
to speculate that the resulting expanding CD4+ T cells have a regulatory function, as otherwise
the disease should rather be accelerated. In fact, the percentage of antigen-specific CD4+
Foxp3+ T cells was moderately increased in mice treated with PS-liposomes loaded with 2.5mi
peptide, when compared to sham group. However, since CD4+ Foxp3- T cells also expanded,
we do not discard that another subset of antigen-specific Foxp3- regulatory T cells [55] could
contribute to the effect of this immunotherapy in the induction of tolerance.
The administration of PS-liposomes filled with autoantigens represents a novel approach to
down-regulate autoimmunity in T1D. We are well aware that the NODmouse strain has some
immunological defects that are not seen in humans [56], but it is an important tool for dissect-
ing tolerance mechanisms and for the design of innovative therapies. PS-liposomes might pro-
vide a new system to co-deliver tolerogenic signals and autoantigens, thus inducing
immunological tolerance recovery.
Conclusions
This study demonstrates that liposomes rich in phosphatidylserine displaying insulin peptides
induce tolerogenic DCs and impair autoreactive T cell proliferation. This antigen-specific im-
munotherapy arrests the autoimmune aggression by apoptotic mimicry, thus decreasing exper-
imental T1D incidence. PS-liposomes can offer a solution with design benefits: customizable,
large-scale production, stability, and uniformity. Although further research is needed, the clini-
cal relevance of the herein proposed immunotherapy could prove to be very important, as it
has translational potential in human diseases that require the reestablishment of immunologi-
cal tolerance.
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Supporting Information
S1 Fig. Viability and purity of T cells used in proliferation assays. Flow cytometry contour
plots of cell size and granularity (FSC and SSC), viability (annexin V-, 7aad-), purity (CD3+),
and T cell subsets (CD4 and CD8 expression, gated on CD3+ T cells) of negative selected T
cells from NODmice spleen.
(TIF)
S2 Fig. Cytokine production in T cell proliferation experiments induced by DCs after the
capture of liposomes. Levels of IL-6, TNF, TGF-β, IL-10, IL-2 and IL-4 were measured in su-
pernatants from T cell proliferation experiments induced by iDCs, DCs loaded with empty
liposomes (PS-lipo) and DCs loaded with liposomes with insulin peptides (PSAB-lipo) in
basal conditions (white bars) or after 24 hours with LPS (black bars). Results are expressed as
mean±SEM from four independent experiments. Comparisons within each group and between
paired maturation conditions were not able to detect significant differences (p<0.05, Wilcoxon
test). Values under dotted line are below the standard.
(TIF)
S3 Fig. In vivo expansion of antigen-specific CD4+ Foxp3+ T cells 4 days after i.p. adminis-
tration of PS2.5mi-liposomes to NOD.Foxp3EGFP mice. A) Representative flow cytometry
contour plots of the percentage of 2.5mi+ CD4+ Foxp3+ T cells in the spleen, pancreatic lymph
nodes (PLN) and mediastinal lymph nodes (MDLN) (gated on CD19-, CD8-, F4/80-, CD11c-,
PI- and CD4+ cells) in the sham group and after the administration of PS2.5mi-liposomes. Left
panel: Ag7/2.5mi tetramer staining. Right panel: control staining with Ag7/GPI282–292 tetramer.
B) Percentage of 2.5mi+ CD4+ Foxp3- T cells (black bars) and percentage of 2.5mi+ CD4+
Foxp3+ T cells (white bars) in the spleen, PLN and MDLN from 3–5 mice after the administra-
tion of saline solution or PS2.5mi-liposomes. Results are expressed as mean±SD. Comparisons
between groups showed significant differences (p<0.05, MannWhitney test).
(TIFF)
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